{"id":"phosphorus-binder","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances (nausea, constipation, diarrhea)"},{"rate":null,"effect":"Hypercalcemia"},{"rate":null,"effect":"Abdominal discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Phosphorus binders are compounds that form complexes with dietary phosphate in the GI lumen, making phosphorus unavailable for absorption. This reduces serum phosphate concentrations, which is critical in managing hyperphosphatemia in patients with chronic kidney disease or end-stage renal disease who cannot adequately excrete phosphorus through the kidneys.","oneSentence":"Phosphorus binders reduce serum phosphate levels by binding dietary phosphorus in the gastrointestinal tract, preventing its absorption.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:55:19.061Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperphosphatemia in patients with chronic kidney disease"},{"name":"Hyperphosphatemia in patients on dialysis"}]},"trialDetails":[{"nctId":"NCT03633708","phase":"PHASE3","title":"A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis","status":"RECRUITING","sponsor":"Amgen","startDate":"2019-04-29","conditions":"Secondary Hyperparathyroidism, Chronic Kidney Disease","enrollment":56},{"nctId":"NCT06933472","phase":"PHASE3","title":"A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China","status":"RECRUITING","sponsor":"Alebund Pharmaceuticals","startDate":"2025-06-13","conditions":"Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease)","enrollment":264},{"nctId":"NCT07080840","phase":"NA","title":"Phosphorus Education and Adherence in Hemodialysis Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Jen-Ai Hospital Institutional Review Board","startDate":"2024-07-29","conditions":"Nursing Education, Hemodialysis","enrollment":45},{"nctId":"NCT06901102","phase":"PHASE1, PHASE2","title":"Effect of Bee Venom on Chronic Kidney Disease-Mineral Bone Disorders in Hemodialysis Patients: a Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2025-04-10","conditions":"Chronic Kidney Disease, Bee Venom, Hemodialysis","enrollment":60},{"nctId":"NCT06218212","phase":"NA","title":"The Effect of Renastart Formula Supplementation in Children With Acute Kidney Injury in Maintaining Normal Serum Electrolytes Levels","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-02-12","conditions":"Acute Kidney Injury","enrollment":24},{"nctId":"NCT05764590","phase":"PHASE2","title":"A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients","status":"COMPLETED","sponsor":"Alebund Pharmaceuticals","startDate":"2023-02-20","conditions":"Chronic Kidney Diseases, Hyperphosphatemia","enrollment":55},{"nctId":"NCT04771780","phase":"PHASE3","title":"Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2021-03-15","conditions":"Hyperphosphatemia","enrollment":213},{"nctId":"NCT03988920","phase":"PHASE4","title":"A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP","status":"COMPLETED","sponsor":"Ardelyx","startDate":"2019-06-15","conditions":"Hyperphosphatemia, End Stage Renal Disease","enrollment":172},{"nctId":"NCT04549597","phase":"PHASE4","title":"Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia","status":"COMPLETED","sponsor":"Ardelyx","startDate":"2020-11-20","conditions":"Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia","enrollment":333},{"nctId":"NCT02209636","phase":"PHASE4","title":"Phosphate Lowering in CKD Trial","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2014-09-15","conditions":"Chronic Kidney Disease, Cardiovascular Disease","enrollment":66},{"nctId":"NCT03079869","phase":"PHASE4","title":"Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2017-05-01","conditions":"Hyperphosphatemia","enrollment":55},{"nctId":"NCT03861247","phase":"PHASE3","title":"Individualized Treatment of Hyperphosphatemia in Maintenance Hemodialysis Patients","status":"COMPLETED","sponsor":"Chen Jing","startDate":"2019-11-29","conditions":"Maintenance Hemodialysis, Hyperphosphatemia","enrollment":123},{"nctId":"NCT01130831","phase":"","title":"Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder Therapy","status":"COMPLETED","sponsor":"Shire","startDate":"2010-04-26","conditions":"End Stage Renal Disease","enrollment":66},{"nctId":"NCT00452478","phase":"PHASE4","title":"Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5","status":"TERMINATED","sponsor":"Shire","startDate":"2007-05-22","conditions":"Kidney Diseases","enrollment":68},{"nctId":"NCT04789876","phase":"NA","title":"Effectiveness of The Phosphate Mobile App on Serum Phosphorus in Adult Hemodialysis Patients With Hyperphosphatemia","status":"COMPLETED","sponsor":"Taylor's University","startDate":"2019-11-01","conditions":"Hyperphosphatemia, End Stage Renal Disease on Dialysis","enrollment":74},{"nctId":"NCT00750295","phase":"PHASE1, PHASE2","title":"A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on Hemodialysis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-02","conditions":"Chronic Kidney Disease","enrollment":60},{"nctId":"NCT04645459","phase":"NA","title":"The Influence of Low Phosphorus in Hemodialysis Patients","status":"UNKNOWN","sponsor":"Taipei Medical University","startDate":"2020-12-03","conditions":"Hemodialysis Patients","enrollment":80},{"nctId":"NCT02688764","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia","status":"TERMINATED","sponsor":"Vifor Fresenius Medical Care Renal Pharma","startDate":"2016-05-26","conditions":"Hyperphosphatemia","enrollment":85},{"nctId":"NCT02492620","phase":"PHASE3","title":"Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D","status":"COMPLETED","sponsor":"Denver Nephrologists, P.C.","startDate":"2015-03","conditions":"Chronic Kidney Disease, Hyperphosphatemia, Iron Deficiency Anemia","enrollment":200},{"nctId":"NCT03603444","phase":"","title":"Reliability of Serum Calcium to Phosphorus (Ca/P) Ratio as an Accurate and Inexpensive Tool to Define Disorders of Ca-P Metabolism","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria di Modena","startDate":"2011-01-01","conditions":"Phosphorus and Calcium Disorders","enrollment":606},{"nctId":"NCT02940743","phase":"NA","title":"Behavioral Management of Phosphorus in Hemodialysis Patients","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2018-04-23","conditions":"Cardiovascular Disease (CKD), Hyperphosphatemia","enrollment":40},{"nctId":"NCT03202407","phase":"PHASE3","title":"Hyperphosphatemia in Children With Chronic Kidney Disease","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-08-01","conditions":"Hyperphosphatemia","enrollment":40},{"nctId":"NCT01581996","phase":"NA","title":"Fosrenol and Phosphorus Balance - Lanthanum Carbonate","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2012-03","conditions":"Chronic Kidney Failure, End-stage Renal Disease, Disorders Associated With Peritoneal Dialysis","enrollment":9},{"nctId":"NCT00648167","phase":"PHASE2","title":"A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)","status":"COMPLETED","sponsor":"Keryx Biopharmaceuticals","startDate":"2008-03","conditions":"Hyperphosphatemia, End-stage Renal Disease","enrollment":55},{"nctId":"NCT01991574","phase":"EARLY_PHASE1","title":"Effect of the Consumption of Ferric Hydroxide Adipate on Urinary Phosphorus Excretion.","status":"COMPLETED","sponsor":"Medical Research Council","startDate":"2009-04","conditions":"Healthy, Chronic Kidney Diseases","enrollment":30},{"nctId":"NCT02755961","phase":"NA","title":"Efficacy of Dietary Education and Education on Phosphate Binder Use in Hemodialysis Patients","status":"COMPLETED","sponsor":"Ajou University School of Medicine","startDate":"2015-07","conditions":"Hyperphosphatemia, End-stage Renal Disease","enrollment":70},{"nctId":"NCT01427907","phase":"PHASE4","title":"Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients","status":"COMPLETED","sponsor":"Fresenius Medical Care North America","startDate":"2011-09","conditions":"Chronic Kidney Disease","enrollment":38},{"nctId":"NCT02531204","phase":"PHASE1","title":"A Study of ASP1585 to Evaluate the Bioequivalence Between ASP1585 Granules and ASP1585 Capsules","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-08","conditions":"Healthy, Urine Phosphorus Excretion","enrollment":60},{"nctId":"NCT01191255","phase":"PHASE3","title":"A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis","status":"COMPLETED","sponsor":"Keryx Biopharmaceuticals","startDate":"2010-10","conditions":"Hyperphosphatemia, Kidney Failure","enrollment":441},{"nctId":"NCT01003223","phase":"NA","title":"Phosphate Kinetic Modeling","status":"COMPLETED","sponsor":"Fresenius Medical Care North America","startDate":"2009-10","conditions":"End Stage Renal Disease, Hyperphosphatemia","enrollment":190},{"nctId":"NCT01161407","phase":"NA","title":"Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease","status":"COMPLETED","sponsor":"Indiana University","startDate":"2010-06","conditions":"Chronic Kidney Disease","enrollment":12},{"nctId":"NCT01341678","phase":"NA","title":"Circadian Rhythm Modulation by Dietary Phosphorus in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Geoffrey Block","startDate":"2011-04","conditions":"Chronic Kidney Disease","enrollment":15},{"nctId":"NCT00843349","phase":"NA","title":"Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Myles Wolf","startDate":"2009-07","conditions":"Kidney Disease","enrollment":43},{"nctId":"NCT00656279","phase":"NA","title":"Intensive Dietary Education to Lower Serum Phosphorus in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2008-04","conditions":"Chronic Kidney Disease","enrollment":24},{"nctId":"NCT01357317","phase":"PHASE3","title":"Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction","status":"UNKNOWN","sponsor":"Salem Veterans Affairs Medical Center","startDate":"2011-06","conditions":"Chronic Kidney Disease","enrollment":120},{"nctId":"NCT01509027","phase":"NA","title":"Study of the Compliance With Phosphorus Restricted Diet and Phosphate Binder Therapy in Hemodialysis Patients","status":"UNKNOWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2012-01","conditions":"Chronic Kidney Disease","enrollment":150},{"nctId":"NCT01116947","phase":"NA","title":"Fosrenol for Enhancing Dietary Protein Intake in Hypoalbuminemic Dialysis Patients (FrEDI) Study","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2010-07","conditions":"End-Stage Renal Disease","enrollment":108},{"nctId":"NCT00438932","phase":"NA","title":"Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2007-01","conditions":"Chronic Kidney Disease","enrollment":16},{"nctId":"NCT01049815","phase":"NA","title":"Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease","status":"COMPLETED","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2005-02","conditions":"End Stage Renal Disease, Hemodialysis, Intimal Media Thickness","enrollment":175}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"AORTIC VALVE INCOMPETENCE"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"CARDIAC DISORDER"},{"count":1,"reaction":"CARDIO-RESPIRATORY ARREST"},{"count":1,"reaction":"CARDIOACTIVE DRUG LEVEL ABOVE THERAPEUTIC"},{"count":1,"reaction":"CHEST DISCOMFORT"},{"count":1,"reaction":"CHEST PAIN"},{"count":1,"reaction":"CORONARY ARTERY DISEASE"},{"count":1,"reaction":"DECREASED APPETITE"},{"count":1,"reaction":"DIALYSIS"}],"_approvalHistory":[],"publicationCount":61,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lanthanum Carbonate","Calcium Acetate"],"phase":"phase_3","status":"active","brandName":"Phosphorus binder","genericName":"Phosphorus binder","companyName":"Salem Veterans Affairs Medical Center","companyId":"salem-veterans-affairs-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Phosphorus binders reduce serum phosphate levels by binding dietary phosphorus in the gastrointestinal tract, preventing its absorption. Used for Hyperphosphatemia in patients with chronic kidney disease, Hyperphosphatemia in patients on dialysis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}